All In Biotech

Drug Trial Radar · NCT00877214

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas

Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,272 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,272

Actual

Start

Apr 1, 2009

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Jurgen BarthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sponsor GmbH
First posted
Apr 7, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.

Conditions

  • Follicular Lymphomas
  • Immunocytomas
  • Marginal Zone Lymphomas
  • Mantle-Cell Lymphomas
  • Lymphocytic Lymphoma
  • Non-Hodgkin's Lymphoma

Interventions

  • RituximabDrug

    Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years

  • Rituximab / observationDrug

    Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 5 years and ongoing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • StiL Head Office; Justus-Liebig-University

    Giessen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.